The FDA approval was based on the same studies, which demonstrated a significant reduction in seizure frequency at all doses studied compared to placebo. Study 013 and 017 showed a statistically significant 56% reduction from baseline in seizure frequency and statistically significant responder rates in all doses, respectively.